- Home
- LION vs BEAM Comparison
LION vs BEAM Comparison
Compare LION & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LION
- BEAM
- Stock Information
- Founded
- LION 1997
- BEAM 2017
- Country
- LION United States
- BEAM United States
- Employees
- LION N/A
- BEAM N/A
- Industry
- LION Movies/Entertainment
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LION Consumer Discretionary
- BEAM Health Care
- Exchange
- LION Nasdaq
- BEAM Nasdaq
- Market Cap
- LION 1.9B
- BEAM 1.7B
- IPO Year
- LION N/A
- BEAM 2020
- Fundamental
- Price
- LION $7.16
- BEAM $25.10
- Analyst Decision
- LION Buy
- BEAM Strong Buy
- Analyst Count
- LION 9
- BEAM 10
- Target Price
- LION $8.88
- BEAM $49.78
- AVG Volume (30 Days)
- LION 2.6M
- BEAM 3.0M
- Earning Date
- LION 11-06-2025
- BEAM 11-04-2025
- Dividend Yield
- LION N/A
- BEAM N/A
- EPS Growth
- LION N/A
- BEAM N/A
- EPS
- LION N/A
- BEAM N/A
- Revenue
- LION $3,986,900,000.00
- BEAM $60,272,000.00
- Revenue This Year
- LION N/A
- BEAM N/A
- Revenue Next Year
- LION $16.90
- BEAM $18.20
- P/E Ratio
- LION N/A
- BEAM N/A
- Revenue Growth
- LION 10.89
- BEAM N/A
- 52 Week Low
- LION $5.55
- BEAM $13.53
- 52 Week High
- LION $8.50
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- LION 60.69
- BEAM 72.69
- Support Level
- LION $7.06
- BEAM $19.57
- Resistance Level
- LION $7.30
- BEAM $21.59
- Average True Range (ATR)
- LION 0.31
- BEAM 1.56
- MACD
- LION 0.07
- BEAM 0.65
- Stochastic Oscillator
- LION 66.67
- BEAM 99.73
About LION Lionsgate Studios Corp. Common Shares
Lionsgate Studios Corp is a motion picture and television studio operations aligned with the STARZ premium subscription platform to bring a varied portfolio of entertainment to consumers around the world. The group has two reportable business segments: the Motion Picture and Television Production reportable segments. Motion Picture consists of the development and production of feature films, the acquisition of North American and world-wide distribution rights. Television Production consists of the development, production, and world-wide distribution of television productions, including television series, television movies and mini-series, and non-fiction programming.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.